Clinical Trial Update: CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating CA-4948 in combination with FOLFOX and a PD-1 inhibitor, with or without trastuzumab, for untreated unresectable gastric and esoph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• CA-4948
• FOLFOX
• PD-1 inhibitor
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Gastric Cancer, Esophageal Cancer | Phase 1 | Status: RECRUITING